Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine 6-glucuronide (M6G) is a major active metabolite of the opioid analgesic morphine, formed in the liver by the enzyme UGT2B7. It acts as a potent agonist at the mu-type opioid receptor, with an affinity equal to or greater than that of morphine itself. M6G is responsible for much of the analgesic effect observed after administration of morphine and can provide pain relief comparable to or exceeding that of its parent compound. Unlike some other metabolites, M6G retains strong analgesic activity and may be associated with fewer side effects such as respiratory depression and postoperative nausea and vomiting. However, it can accumulate to toxic levels in patients with renal impairment due to its primary excretion via the kidneys[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine 6-glucuronide.